Novacyt S.a annual ebitda
2022
2023
2024
2025
Novacyt S.a EBITDA Growth & History (NCYT)
Novacyt S.a's calculated EBITDA was −£8.2M for fiscal 2025.
View full Novacyt S.a company overviewNovacyt S.a annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£8.2M | £23.2M | — |
| 2024 | 2024-12-31 | −£31.4M | −£19.0M | — |
| 2023 | 2023-12-31 | −£12.4M | −£708,000 | — |
| 2022 | 2022-12-31 | −£11.7M | — | — |
Novacyt S.a ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Novacyt S.a's ebitda increased from −£11.7M to −£8.2M, a change of £3.5M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novacyt S.a source filings ↗Community posts
Novacyt grows sales but reports lower margins and reduced cash reserves
Novacyt ($NCYT) reported first-half revenue growth of 18% to £11.6 million, with approximately 9% underlying growth excluding acquired Southern Cross Diagnostics. Instrumentation sales increased about 30%, while clinical products grew more ...
